Oncology

The breakthrough therapy designation was granted based on ongoing data from the ARTEMIS-001 phase 1 open-label, multi-center trial.

Vimseltinib (Deciphera Pharmaceuticals) has a Prescription Drug User Fee Act goal date of February 17, 2025.

The combination is the first and only multi-targeted chemotherapy-free regimen that demonstrated superiority compared with osimertinib for non–small cell lung cancer (NSCLC).

Palliative pharmacists are invaluable assets of oncologic care.

Fam-trastuzumab deruxtecan-nxki has received 4 breakthrough therapy designations, including the latest approval.

Currently, the drug will be studied in the SKYBRIDGE (NCT05652686) trial, a first-in-human, phase 1/2, open-label, dose-escalation and expansion study.

This article discusses clinical data for noncovalent Bruton tyrosine kinase inhibitors (BTKis), novel strategies in CLL, and the practical management of BTKi toxicities.

CAR T-cell therapy in multiple myeloma faces challenges from the immunosuppressive cells in the tumor microenvironment.

This article reviews the efficacy and safety data for bispecific T-cell engagers and the practical considerations for their implementation across various types of practice sites for the historically difficult-to-treat relapsed/refractory B-cell lymphoma population.

Durvalumab is a human monoclonal antibody that targets and binds to PD-L1 to interrupt tumor immune-evasion tactics.

Building off the positive results of ELM-1, the ELM-2 trial found intravenously administered odronextamab was safe and effective in patients with relapsed or refractory follicular lymphoma.

The supplemental biologics license application was granted based on results from the ADRIATIC phase 3 trial among individuals with limited stage small cell lung cancer.

The decision is based positive data from the Deltacel-01 clinical trial.

AC699 is being evaluated for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative (HER2–), estrogen receptor 1-mutated advanced or metastatic breast cancer with disease progression on or after at least 1 line of endocrine-based therapy.

This review explores cytopenia after CAR T-cell therapy, including its risk stratification and management with growth factors, thrombopoietin-receptor agonists, and hematopoietic stem cell boosts.

Axatilimab-csfr (Niktimvo, Incyte Corporation) is a colony stimulating factor-1 receptor-blocking antibody for the treatment of chronic graft-versus-host disease (cGVHD).

Pharmacists play a vital role in therapy selection.

The data builds off prior studies supporting bendamustine-rituximab as a first-line treatment for patients with non-Hodgkin lymphoma.

In her first Editor’s Note as editor in chief of PPFO, Zahra Mahmoudjafari shares reflections on a summer filled with conferences.

The trial evaluated a fixed-dose combination of vibostolimab and pembrolizumab in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer.

Pharmacists will play an integral role in this evolving field, from patient education and monitoring AEs to new therapeutic developments and treatment protocols.

A variety of signs and symptoms of lymphoma were reported, including fever, stomach discomfort, and weight loss.

The study is expected to include 460 individuals that will be randomly treated with 12mg of ifinatamab deruxtecan or chemotherapy chosen by the health care provider.

Statins and non-statin cholesterol-lowering agents show potential in reducing the risk of liver cancer.

Dan Schrum discusses the integral role of pharmacy specialists in translating clinical trial results to clinical practice.

The findings may lead to the development of diagnostic and therapeutic targets to prevent worsening disease in patients.

Investigators will examine the combination with pembrolizumab and lenvatinib in patients with HER2-expressing endometrial cancer.

Isatuximab (Sarclisa; Sanofi) in combination with standard-of-care significantly improved progression-free survival in patients with newly diagnosed multiple myeloma.

Dan Schrum highlights the crucial role of lymphodepletion in enhancing the effectiveness of CAR T cell therapy.

Denileukin diftitox-cxdl is the only therapy approved for cutaneous T-cell lymphoma that targets IL-2 receptors in malignant T-cells and Tregs.